

A Novel Synthesis of 1-OXA-HPMPA: A Potent Antiviral Agent Against Herpesviruses


Choung Un Kim*, Bing Y. Luh, and John C. Martin¹

Bristol-Myers Squibb Company, Pharmaceutical Research Institute
5 Research Parkway, Wallingford, Connecticut 06492-7660

Abstract: A facile synthesis of 1-oxa-HPMPA **2** was achieved via a novel strategy of coupling 9-hydroxyadenine **13** and enol ether phosphonate **11**. The newly synthesized 1-oxa analogue of HPMPA exhibited potent antitherpesvirus activity.


Key Words: HPMPA; 1-oxa-HPMPA; Herpesviruses

Recently, a new acyclic nucleoside phosphonate derivative, (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine (HPMPA: **1**) has been described as a potent and a selective inhibitor of a broad range of DNA viruses.^{2,3} The diphosphorylated derivative of HPMPA, which corresponds to the antivirally active triphosphate of acyclovir (**3**)⁴, is a potent inhibitor of herpesvirus DNA polymerase.³ Previous studies by Beecham group identified 9-(3-hydroxypropoxy)guanine (**4**), an isosteric isomer of acyclovir, as a potent antitherpesvirus agent.⁵ In continuation of our studies on nucleotide analogues as antiviral agents,^{6,7} we have undertaken the synthesis of 1-oxa-HPMPA (**2**) to investigate structure activity relationships of this class of compounds.




The basic strategy that we selected for the construction of the hydroxymethyl substituted acetal functionality in **2** relies on the regiospecific addition of an appropriately protected 7-hydroxyadenine to enol ether phosphonate **6** under mediation of suitable electrophile (X) (Scheme I). In this sequence, the phenylselenenyl derivative **7** would serve as a precursor of enol ether **6**. However, this route requires conversion of the electrophile (X) to the hydroxyl functionality to complete the synthesis of **2**.

SCHEME I



Preparation of requisite enol ether 11 commenced with 2-(phenylselenenyl)ethanol (8)⁸ which was first converted to chloromethyl ether 9 with $\text{CH}_2\text{O}/\text{HCl}$ (in CH_2Cl_2 at 0°C for 2h) (Scheme II). The Arbuzov reaction of 9 with triethyl phosphite (at 120°C for 3 h) gave phosphonate 10 (92% from 8). Oxidation of 10 with sodium periodate (2 equiv in methanol-water at 23°C for 30 min) followed by thermolysis (benzene reflux for 45 min) of the selenoxide produced enol ether 11 (92%). Next, we prepared N6-amine protected 9-hydroxyadenine. The selection of the N6-amine protecting group was critical for the electrophilic addition of 9-hydroxyadenine to enol ether 11. Among protecting groups investigated, the dimethoxytrityl group⁹ was found to give the most satisfactory result for the addition reaction. This protection also offered advantage of the selective hydrogenolysis of the benzyl group in 12 (84%) which was in turn, readily prepared by tritylation of 9-benzyloxyadenine¹⁰ (90%). With enol ether 11 and N6-trityl-9-hydroxyadenine 13 in hand, we turned our attention to the coupling of these two units. Oxidative coupling of 11 and 13 in the presence of 3-chloroperbenzoic acid gave a complex mixture. It appears that 9-hydroxyadenine is quite sensitive toward oxidation. Attempts to prepare an epoxide of 11 with various peroxides or dimethyldioxirane were not successful. However, when N-iodosuccinimide was added to a mixture of 11 and 13 (1 equiv each) in CH_2Cl_2 at 0°C , iodide 14 was isolated in 65% yield.¹¹ Conversion of iodide 14 to acetate 15 was achieved in 62% yield by treatment with tetraethylammonium acetate (10 equiv in DMF at 60°C for 4 h). Treatment of 15 with trimethylsilylbromide (9 equiv in DMF at 23°C for 6h) followed by neutralization with ammonium hydroxide gave mono ammonium salt 16 (45%) after reverse-phase column purification. Interestingly, 1-oxa-HPMPA (16) thus prepared, was quite acid stable despite the presence of the acetal functionality. A pH 1.5 solution of 16 showed no sign of degradation after 24 h at 23°C as evidenced by NMR and HPLC analysis.

SCHEME II



In an antiviral test carried out in Vero (for herpes simplex virus type 2: HSV-2) and MRC-5 (human cytomegalovirus: HCMV) cells, the IC₅₀ (50% inhibitory concentration) for inhibition of the replication of HSV-2 and HCMV were 2.6 and 1.0 µg/mL for 16 (cf 40 and 0.5 µg/mL for HPMPA) without any sign of toxicity for the cell monolayer up to 100 µg/mL.

Acknowledgement: The authors wish to thank Dr. M.J.M. Hitchcock and his coworkers for antiviral assays.

References and Notes

1. Present address: Gilead Sciences, 344 Lakeside Drive, Foster City, CA 94404.
2. De Clercq, E.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; Maudgal, P.C. *Nature*. **1986**, 323, 464.
3. Holy, A.; De Clercq, E.; Votruba, I. ACS Symposium Series No. 401 (J.C. Martin, Ed.), *American Chemical Society*, **1989**, pp. 51-71.
4. Elion, G.B.; Furman, P.A.; Fyfe, J.A.; De Miranda, P.; Beauchamp, L.; Schaeffer, J.J. *Proc. Natl. Acad. Sci., USA*. **1977**, 74, 5716.
5. Harnden, M.R.; Wyatt, P.G.; Boyd, M.R.; Sutton, D. *J. Med. Chem.* **1990**, 33, 187.
6. Kim, C.U.; Misco, P.F.; Luh, B.Y.; Hitchcock, M.J.M.; Ghazzouli, I.; Martin, J.C.J. *Med. Chem.* **1991**, 34, 2286.
7. Kim, C.U.; Luh, B.Y.; Martin, J.C.; *J. Org. Chem.* **1991**, 56, 2642.
8. Rollin, P.; Bencomo, V.V.; Sinay, P. *Synthesis*. **1984**, 134.
9. Kawana, M.; Takeuchi, K.; Ohba, T.; Kuzuhara, H. *Bull. Chem. Soc. (Japan)*, **1988**, 61(7), 2437.
10. Watson, A.A. *J. Org. Chem.* **1977**, 42, 1610.
11. For examples of this type of reactions: Friesen, R.W.; Danishefsky, S.J. *J. Am. Chem Soc.* **1989**, 111, 6656, and references cited therein.

(Received in USA 1 October 1991)